Abstract ES5-2: ES5-2 Non-endocrine strategies: Beyond the estrogen receptor

Abstract

Abstract Powel Brown, Parijatham Thomas, Abhijit Mazumdar, Diane Weber, Robin Coyne, Lana Vornik, Terry Bevers, and Abenaa Brewster Department of Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center; Houston, TX. Breast cancer prevention has been demonstrated to be possible using anti-estrogen drugs. However, these drugs only prevent the development of estrogen receptor-positive breast cancers, and are often not acceptable to women. Therefore, there has been a major effort to develop more acceptable breast cancer preventive strategies. In this presentation I will review the current approaches to breast cancer prevention, with a focus on risk-based preventive interventions, including behavioral measures to reduce breast cancer risk in average risk individuals, and drug-based interventions in high risk individuals. While anti-estrogen hormonal therapies are still the most effective preventive therapy other than prophylactic breast surgery, other strategies are being tested that offer great promise. Interventions that have been shown to be effective in preclinical studies include novel molecularly targeted drugs (such as PARP inhibitors, mTOR inhibitors, and RXR-selective retinoids), re-purposed drugs (such as metformin and statin drugs), and vaccines. In addition, novel schedules and formulations are being tested to avoid the toxicity of traditionally used drugs such as tamoxifen and aromatase inhibitors. High-risk individuals who may particularly benefit from preventive therapy include women with premalignant lesions (atypical hyperplasia and lobular carcinoma-in-situ lesions), ductal carcinoma-in-situ breast cancers, or a genetic predisposition to breast cancer. With continued advances in molecularly targeted drug development and improved personalized risk assessment, effective, safe, and acceptable breast cancer preventive strategies will soon be available. Citation Format: Brown P. ES5-2 Non-endocrine strategies: Beyond the estrogen receptor [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr ES5-2.